EDIT vs SRPT · rev $32.3M vs rev $1.90B
Editas Medicine Inc (EDIT) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
EDIT currently screens at market cap $375.2M. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the EDIT and SRPT stock pages for the full models.
Not investment advice.